Erik C. Blachford - 01 Mar 2026 Form 4 Insider Report for ZILLOW GROUP, INC. (ZG)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
03 Mar 2026, 17:03:03 UTC
Prior SEC filing
25 Feb 2026
Next SEC filing
09 Jun 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Shannon Cartales Attorney-in-Fact

Key filing fact

Erik C. Blachford filed Form 4 for ZILLOW GROUP, INC. (ZG) on 03 Mar 2026.

Key facts

  • This page summarizes Erik C. Blachford's Form 4 filing for ZILLOW GROUP, INC. (ZG).
  • 4 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 03 Mar 2026, 17:03.

Change

  • Previous filing in this sequence was filed on 25 Feb 2026.
  • Current net transaction value: -$41,393.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001184251 Primary reporting owner

BLACHFORD ERIK C

Relationship
Director
Address
C/O ZILLOW GROUP, INC., 1301 SECOND AVENUE, FLOOR 36, SEATTLE
Signature
/s/ Shannon Cartales Attorney-in-Fact
Signature date
03 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ZG transaction

Class C Capital Stock

Award

Transaction value
$0
Shares
+3,166
Change %
+7.5%
Price
$0.000000
Shares after
45,126
Date
01 Mar 2026
Ownership
Direct
Footnotes
F1
ZG transaction

Class C Capital Stock

Other

Transaction value
$0
Shares
-8,417
Change %
-19%
Price
$0.000000
Shares after
36,709
Date
02 Mar 2026
Ownership
Direct
Footnotes
F2
ZG transaction

Class C Capital Stock

Sale

Transaction value
$41,393
Shares
-966
Change %
-2.6%
Price
$42.85
Shares after
35,743
Date
03 Mar 2026
Ownership
Direct
Footnotes
F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ZG transaction Derivative

Stock Option (right to buy)

Award

Transaction value
$0
Shares
+9,498
Change %
Price
$0.000000
Shares after
9,498
Date
01 Mar 2026
Ownership
Direct
Underlying class
Class C Capital Stock
Underlying amount
9,498
Exercise price
$44.62
Footnotes
F4
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

Represents a grant of restricted stock units that will vest as to 1/4th of the total amount of shares subject to the grant after each three-month period following the grant date such that the restricted stock units are fully vested on the one-year anniversary of the grant date.

Footnote F2

Reflects a transfer of directly held shares to the reporting individual's former spouse in connection with a divorce settlement. The reporting individual no longer beneficially owns the securities transferred.

Footnote F3

The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2025.

Footnote F4

1/4th of the shares subject to the option will vest and become exercisable after each-three-month period following the grant date such that the option will be fully vested and exercisable on the one-year anniversary of the grant date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .